Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

NCT05260528 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nice as lead sponsor.

NCT NCT05260528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05260528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Lead sponsor
Centre Hospitalier Universitaire de Nice
Phase
Phase 2
Overall status
Recruiting
Start date
May 3, 2023
Completion date
February 2, 2030
Enrollment
248 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia